

October 21, 2019

The Manager- Listing
BSE Limited
Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai - 400001

The Manager- Listing
National Stock Exchange of India Limited
Exchange plaza, 5th Floor, Plot No. C/1, G Block
Bandra –Kurla Complex, Bandra (E),
Mumbai - 400051

Dear Sir(s),

Subject: Launch of durvalumab (Imfinzi™) in India

We refer to our communication dated June 21, 2018 with regard to the receipt of Import and Market Permission in Form 45 (Marketing Authorization) from the Drugs Controller General of India for durvalumab (Imfinzi™).

With regard to the same, we now wish to update that AstraZeneca Pharma India Limited will launch durvalumab (Imfinzi™) in India on October 22, 2019.

Durvalumab (Imfinzi™) provides a treatment option for patients with locally advanced, unresectable Non-Small Cell Lung Cancer (NSCLC) and metastatic urothelial carcinoma.

Durvalumab (Imfinzi™) is a product of AstraZeneca global. As of April 30, 2019, durvalumab is approved in 18 countries for urothelial cancer and over 30 countries for NSCLC including US, EU, Japan and Brazil.

Kindly take the same on record.

For **AstraZeneca Pharma India Limited**



Pratap Rudra
Company Secretary & Legal Counsel

